Cell-specific computational modeling of the PIM pathway in acute myeloid leukemia

Cancer Research

Volumn 77, Issue 4, 2017, Pages 827-838

  Silverbush, Dana ^a,b   Grosskurth, Shaun ^c   Wang, Dennis ^c   Powell, Francoise ^c   Gottgens, Berthold ^d   Dry, Jonathan ^c   Fisher, Jasmin ^b,e  

^a TEL AVIV UNIVERSITY   (Israel)

^b MICROSOFT RESEARCH   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; AZD 1208; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE PIM 1; PROTEIN KINASE TYK2; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SELUMETINIB; UNCLASSIFIED DRUG; AZD1208; BIPHENYL DERIVATIVE; FLT3 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PIK3CA PROTEIN, HUMAN; PROTO-ONCOGENE PROTEINS PIM; THIAZOLIDINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE MUTATION; GENETIC VARIABILITY; LEUKEMIA CELL LINE; PHENOTYPIC VARIATION; PROTEOMICS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPUTER SIMULATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LEUKEMIA, MYELOID, ACUTE; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; THIAZOLIDINES;

EID: 85014058591     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1578     Document Type: Article

References (31)

1. Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 2015;6:6169.
2. Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ,et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 2014;32:1202-12.
3. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014;15:R47.
4. Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014;4:5193.
5. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86.
6. Wang H, Hu H, Zhang Q, Yang Y, Li Y, Hu Y, et al. Dynamic transcriptomes of human myeloid leukemia cells. Genomics 2013;102:250-6.
7. Cancer Genome Atlas Research Network TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74.
8. Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014;123:905-13.
9. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor thatdisplays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013;12:19.
10. Klco JM, Spencer DH, Miller CA, GriffithM, LamprechtTL, O'LaughlinM, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25:379-92.
11. Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol 2014;167:69-79.
12. Kauffman S. Homeostasis and differentiation in random genetic control networks. Nature 1969;224:177-8.
13. Kauffman S. Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol 1969;22:437-67.
14. Huang S. Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery. J Mol Med 1999;77:469-80.
15. Sanchez L, Thieffry D. A logical analysis of the Drosophila gap-gene system. J Theor Biol 2001;211:115-41.
16. Schaub MA,Henzinger TA, Fisher J.Qualitative networks:asymbolic approach to analyze biological signaling networks. BMC Systems Biol 2007;1:4.
17. Benque D, Bourton S, Cockerton C, Cook B, Fisher J, Ishtiaq S, et al. Bma: visual tool for modeling and analyzing biological networks. Computer Aided Verification (CAV) 2012;686-92.
18. Chuang R, Hall BA, Benque D, Cook B, Ishtiaq S, Piterman N, et al. Drug target optimization in chronic myeloid leukemia using innovative computational platform. Sci Rep 2015;5:8190.
19. Saadatpour A, Albert R. A comparative study of qualitative and quantitative dynamic models of biological regulatory networks. EPJ Nonlinear Biomed Phys 2016;4:5.
20. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv 2012;1207.3907.
21. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
22. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 1989;86:8857-61.
23. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25:1182-8.
24. Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-73.
25. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92.
26. Yuan LL, Green AS, Bertoli S, Grimal F, Mansat-De Mas V, Dozier C, et al. Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia. Leukemia 2014;28:293-301.
27. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis 2010;15:795-804.
28. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006;66:3737-46.
29. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012;26:1195-202.
30. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput Biol 2011;7:e1001099.
31. Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 2007;25:30-7.